2021年6月に『家庭医学およびプライマリケアのジャーナル』に掲載された「南インドのコインバトールの田舎地域における避妊普及率とその影響要因に関する研究」という記事によると、避妊普及率は75%であることがわかりました。最も使用されている避妊方法は、結紮手術（81.6%）と子宮内避妊具（6.3%）でした。また、同じ情報源によると、避妊の使用は、女性の年齢、宗教、教育状況、社会経済的状況、雇用状況、子どもの数、結婚年齢、初産年齢と統計的に有意に相関していることがわかりました。

同様に、2021年11月にオルガノンは、ケベックのケベック健康保険公社（RAMQ）においてNEXPLANON（エトノゲストレル持続放出皮下インプラント）の公開上場を発表しました。同様に、2021年6月にセベラファーマシューティカルズ社は、PRAヘルスサイエンスと共同で長期作用性可逆的子宮内システムであるLevoCeptの避妊効果、安全性、および耐容性を評価するための第III相臨床試験を実施しています。

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

    • 4.2.1 性感染症（STD）に対する意識の向上

    • 4.2.2 意図しない妊娠の増加

    • 4.2.3 政府のイニシアティブの高まり

  • 4.3 市場の抑制要因

    • 4.3.1 避妊具の使用に伴う副作用について

  • 4.4 ポーターのファイブフォース分析

    • 4.4.1 新規参入の脅威

    • 4.4.2 買い手・消費者の交渉力

    • 4.4.3 サプライヤーの交渉力

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 タイプ別

    • 5.1.1 コンドーム

    • 5.1.2 ダイヤフラム

    • 5.1.3 頚椎用キャップ

    • 5.1.4 スポンジ

    • 5.1.5 ヴァージナルリング

    • 5.1.6 子宮内避妊器具（IUD）

    • 5.1.7 その他のタイプ

  • 5.2 男女別

    • 5.2.1 男性

    • 5.2.2 女性

  • 5.3 地域別

    • 5.3.1 北米

      • 5.3.1.1 米国
      • 5.3.1.2 カナダ
      • 5.3.1.3 メキシコ

    • 5.3.2 ヨーロッパ

      • 5.3.2.1 ドイツ
      • 5.3.2.2 英国
      • 5.3.2.3 フランス
      • 5.3.2.4 イタリア
      • 5.3.2.5 スペイン
      • 5.3.2.6 その他のヨーロッパ

    • 5.3.3 アジア太平洋

      • 5.3.3.1 中国
      • 5.3.3.2 日本
      • 5.3.3.3 インド
      • 5.3.3.4 オーストラリア
      • 5.3.3.5 韓国
      • 5.3.3.6 その他のアジア太平洋

    • 5.3.4 中東・アフリカ

      • 5.3.4.1 GCC地域
      • 5.3.4.2 南アフリカ
      • 5.3.4.3 その他の中東・アフリカ

    • 5.3.5 南米

      • 5.3.5.1 ブラジル
      • 5.3.5.2 アルゼンチン
      • 5.3.5.3 その他の南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 AbbVie (Allergan PLC)

    • 6.1.2 Bayer AG

    • 6.1.3 Cooper Surgical Inc

    • 6.1.4 Viatris, Inc. (Mylan Laboratories)

    • 6.1.5 Pfizer Inc

    • 6.1.6 Teva Pharmaceutical Industries Ltd

    • 6.1.7 DKT International

    • 6.1.8 Pregna International Limited

    • 6.1.9 Reckitt Benckiser

• 7 市場機会と今後の動向

The Contraceptive Devices Market size is estimated at USD 12.72 billion in 2024, and is expected to reach USD 16.75 billion by 2029, growing at a CAGR of 5.65% during the forecast period (2024-2029).

The COVID-19 pandemic has impacted the growth of the studied market. Initially, the global COVID-19 outbreak and the lockdown scenario in the country have imposed some challenges on the market, as hospitals and clinics were forced to suspend services to prevent the spread of the SARS-CoV-2 virus. The restrictions imposed by the government have significantly impacted the growth of the studied market during the initial period of the pandemic. For instance, according to an article published in March 2022, titled 'Effect of the COVID-19 pandemic on contraceptive prescribing in general practice: a retrospective analysis of English prescribing data between 2019 and 2020', it has been observed that the use of long-acting contraceptives decreased, with implants by 76%, intrauterine systems by 79% and intrauterine devices by 76%. However, with the released COVID-19 restrictions and resumed services, the studied market is expected to grow over the forecast period.

Certain factors that are propelling the market growth are increasing awareness about sexually transmitted diseases, the rising rate of unintended pregnancies, and growing government initiatives.

Unwanted pregnancies are becoming more prevalent globally and are a major cause for concern. For instance, according to the United Nations Population Fund, in March 2022, unintended pregnancies accounted for about half of all pregnancies worldwide, with 121 million occurring each year. As per the same source, over 60% of unplanned pregnancies end in abortion, with an estimated 45% of all abortions being unsafe, resulting in 5%-13% of all maternal fatalities, putting the world's capacity to meet the "Sustainable Development Goals" at risk. Thus, the high rate of unintended pregnancies and unsafe abortions are expected to increase the demand for contraceptive devices, which in turn is anticipated to propel market growth.

In addition, the rising prevalence of sexually transmitted diseases among the population is expected to increase market growth. For instance, according to the report published by the Centers for Disease Control and Prevention in April 2022, it reported that around 133,945 cases of all stages of syphilis were noted,which includes 41,655 cases of primary and secondary syphilis which is considered the most infectious stages of the disease. It also reported an increase of 6.8% in Syphilis during the period 2019 to 2020. The same report also indicated that around 2,148 cases of congenital syphilis were reported in 2020, which includes 149 congenital syphilis-related stillbirths and infant deaths. Additionally, according to the data published by the World Health Organization, in November 2021, it has been observed that around 374 million new infections with one of four sexually transmitted diseases - chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million) and trichomoniasis (156 million) were recorded in 2020. Thus, the rising burden of sexually transmitted diseases is expected to increase the demand for contraception to avoid getting diseases, thereby propelling market growth.

However, the side effects associated with the use of contraceptive devices are likely to impede the market growth over the forecast period.

Contraceptive Devices Market Trends

Female Segment is Expected to Dominate the Contraceptive Devices Market Over the Forecast Period

The female segment in the contraceptive devices market is expected to witness significant growth over the forecast period owing to the increased adoption of contraceptive devices, rising sexually transmitted diseases, and a growing number of unintended pregnancies.

According to an article published by the Journal of Family Medicine and Primary Care, in June 2021, titled 'A study on contraceptive prevalence rate and factors influencing it in a rural area of Coimbatore, South India', the contraceptive prevalence rate was found to be 75%. The most used contraceptive methods were tubectomy (81.6%), and intrauterine devices (6.3%). In addition, as per the same source, the use of contraception was found to be statistically significantly correlated with the women's older age, religion, educational status, socioeconomic status, employment status, number of living children, age at marriage, and age at first childbirth.

Additionally, according to an article published by BioMed Central, in January 2020, titled 'Exploring young women's reasons for adopting intrauterine or oral emergency contraception in the United States: a qualitative study', it has been observed that emergency intra-uterine devices are important and acceptable options among women owing to their benefits.

Furthermore, the increasing company focus on adopting various business strategies such as product launches, listing products in the countries, mergers, and company spin-offs are likely to boost the growth of the market over the forecast period. For instance, In January 2022, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Ontario (Ontario Drug Benefit Program), British Columbia (BC PharmaCare), and Nova Scotia (Nova Scotia PharmaCare).

Similarly, in November 2021, Organon announced the public listings for NEXPLANON (etonogestrel extended-release subdermal implant) in Quebec under the Régie de l'assurance Maladie du Québec (RAMQ). Similarly, in June 2021, Sebela Pharmaceuticals Inc., in collaboration with PRA Health Sciences is conducted phase III clinical trial to assess LevoCept, a long-acting reversible intrauterine system for contraceptive efficacy, safety, and tolerability.

Thus, owing to the aforementioned factors, the market is expected to grow significantly during the forecast period.

North America is Expected to Dominate the Contraceptive Devices Market Over the Forecast Period

North America is expected to dominate the contraceptive devices market over the forecast period owing to the factors such as the rising cases of unwanted pregnancies and high abortion rates, the presence of sophisticated healthcare infrastructure, the high adoption rate of contraceptive devices, and the rising number of government initiatives.

In addition, the rising number of sexually transmitted diseases among the population in the region is also contributing to the growth of the market in the region. For instance, in April 2022, a report published by the Centers for Disease Control and Prevention (CDC) titled 'Sexually Transmitted Disease Surveillance, 2020', stated that STDs remain a significant public health concern in the United States. According to the same source, Chlamydia trachomatis infection was the most prevalent notifiable sexually transmitted infection in the United States in 2020 with a total of 1,579,885 cases reported to the Centers for Disease Control and Prevention (CDC). In addition, as per the same source, 677,769 different gonorrhea infections were reported in the United States, in 2020. Thus, the rising burden of these diseases among the population is expected to increase the demand for male condoms which protect against pathogens such as gonorrhea, herpes simplex virus (HSV), hepatitis B, HIV, and chlamydia which are expected to propel the market growth in the region over the forecast period.

Furthermore, several organizations are also engaged in the implementation of strategic initiatives in the country. For instance, as per the Bill and Melinda Gates Foundation data published in 2022, the foundation is aiming to offer USD 280 million per year from 2021 to 2030 for developing new and improved contraceptive technologies, support family planning programs that reflect the preferences of local communities and enable women and girls to be in control of their contraceptive care.

Thus, owing to the aforementioned factors, the market is expected to grow significantly during the forecast period.

Contraceptive Devices Industry Overview

The contraceptive devices market is fragmented with the presence of key market players. The majority of the contraceptive devices are being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market studied. Moreover, Asia-Pacific has been witnessing the emergence of some small players due to the rise of awareness. This has also helped the studied market to grow.Some of the key players in the market are AbbVie (Allergan PLC), Bayer AG, Cooper Surgical Inc., Reckitt Benckiser, Pregna International Limited and Teva Pharmaceutical Industries Ltd.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Increasing Awareness about Sexually Transmitted Diseases (STDs)

    • 4.2.2 Rising Rate of Unintended Pregnancies

    • 4.2.3 Rise in Government Initiatives

  • 4.3 Market Restraints

    • 4.3.1 Side Effects Associated with the Use of Contraceptive Devices

  • 4.4 Porter's Five Force Analysis

    • 4.4.1 Threat of New Entrants

    • 4.4.2 Bargaining Power of Buyers/Consumers

    • 4.4.3 Bargaining Power of Suppliers

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Type

    • 5.1.1 Condoms

    • 5.1.2 Diaphragms

    • 5.1.3 Cervical Caps

    • 5.1.4 Sponges

    • 5.1.5 Vaginal Rings

    • 5.1.6 Intra Uterine Device (IUD)

    • 5.1.7 Other Types

  • 5.2 By Gender

    • 5.2.1 Male

    • 5.2.2 Female

  • 5.3 Geography

    • 5.3.1 North America

      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

    • 5.3.2 Europe

      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe

    • 5.3.3 Asia-Pacific

      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific

    • 5.3.4 Middle East & Africa

      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa

    • 5.3.5 South America

      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 AbbVie (Allergan PLC)

    • 6.1.2 Bayer AG

    • 6.1.3 Cooper Surgical Inc

    • 6.1.4 Viatris, Inc. (Mylan Laboratories)

    • 6.1.5 Pfizer Inc

    • 6.1.6 Teva Pharmaceutical Industries Ltd

    • 6.1.7 DKT International

    • 6.1.8 Pregna International Limited

    • 6.1.9 Reckitt Benckiser

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS